GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Research & Development

Orphazyme AS (CHIX:ORPHAC) Research & Development : kr229.94 Mil (TTM As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Orphazyme AS's Research & Development for the three months ended in Jun. 2022 was kr0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2022 was kr229.94 Mil.

Orphazyme AS Research & Development Historical Data

The historical data trend for Orphazyme AS's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Research & Development Chart

Orphazyme AS Annual Data
Trend Jun14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Research & Development
Get a 7-Day Free Trial 72.66 154.95 218.14 261.14 229.94

Orphazyme AS Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 166.98 94.16 - 229.94 -

Orphazyme AS Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was kr229.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orphazyme AS  (CHIX:ORPHAc) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Orphazyme AS Research & Development Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS (CHIX:ORPHAC) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Research & Development
Comparable Companies
Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200
Website
https://www.orphazyme.com
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines